NCT00957229View on ClinicalTrials.gov

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Basal Cell Nevus SyndromeGorlin Syndrome
Interventions
DRUG

GDC-0449

capsule, 150 mg, one pill daily, 18 months

Trial Locations (2)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York

94609

Children's Hospital Oakland Research Institiute, Oakland

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

UCSF Benioff Children's Hospital Oakland

OTHER